Value of targeting intervention technology in autologous peripheral blood stem cells therapy of type 2 diabetes mellitus

DING Ming-chao,WANG Yi-zhong,WANG Bin,WANG Hong,DONG Song,CUI Li-qin,LEI Lei,MENG Dan-ping,XU Jing

DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2012.17.039

2012-01-01

Abstract:Objective To investigate clinical efficacy and safety of transcatheter autologous peripheral blood stem cells infusion treatment of type 2 diabetes.Methods 144 cases of type 2 diabetes were divided into two groups:96 cases in observation group received transcatheter stem cell infusion therapy,while 48 cases in control group received conventional treatment.With 12 months follow-up,on the basis of good blood glucose control,HbA1c,the area under C peptide curve,insulin medication changes and security on post-treatment 3 months,6 months,12 months were calculated.Results HbA1c of patients in both groups improve significantly comparing with those before treatment,no significant difference between the two groups.3 months after treatment,there was no statistical difference on the area under C peptide curve between the two groups,however,C peptide level of the observation group was significantly increased 3 months after treatment comparing with counterpart before treatment,and the difference was statistically significant;and on 6 and 12 months after treatment,there were significant differences on the area under C peptide curve between two groups.Also,29.2% of observation group patients reached insulin reduction≥50% after 12 months treatment,while reached 100% insulin reduction in 17.7% patients,and completely drug withdrawal in up to 13.5% patients.In contrast,no case in control group reached insulin reduction≥50%.Conclusions Transcatheter autologous peripheral blood stem cells infusion treatment of type 2 diabetes can disable or reduce hypoglycemic drugs by improving pancreatic function and increasing pancreas insulin secretion;Moreover,the safety of the treatment method is considerable.